SOLICITATION NOTICE
65 -- GeoMx Consumables
- Notice Date
- 8/17/2021 5:51:45 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2086069
- Response Due
- 8/27/2021 10:00:00 AM
- Archive Date
- 09/11/2021
- Point of Contact
- RITA DAVIS, Phone: 3017617461
- E-Mail Address
-
rita.davis@nih.gov
(rita.davis@nih.gov)
- Description
- �The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Nanostring Technologies, Inc., 530 Fairview Ave N, Seattle, WA 98109 to procure consumable fluids for the GeoMX Digital Spatial Profiler. The DSP technology in a novel technology that uses DNA oligo tags covalently linked to detection reagents (primary antibodies or mRNA-binding probes) via a UV photocleavable linker to identify targets in situ and enable quantitation via the standard nCounter technology ex situ. The assay relies upon antibody or RNA probes coupled to photocleavable oligonucleotide tags. After binding of probes to slide-mounted formalin fixed paraffin-embedded (FFPE) tissue sections, the oligonucleotide tags are released from discrete regions of the tissue via UV exposure. Released tags are quantitated in an nCounter assay, and counts are mapped back to tissue location, yielding a spatially-resolved digital profile of analyte abundance. NanoString�s Digital Spatial Profiling technology detects and quantifies proteins and RNA at significantly higher plex (currently >40-plex and 96-plex, respectively, with potential for up to 1000- plex) with spatial resolution using antibodies or RNA probes conjugated to photo-cleavable DNA oligos that are quantified ex situ with molecular digital color-coded �barcodes� from specific regions of interest (ROI) on FFPE tissue. Barcodes are quantitated digitally with a dynamic range of over 5 logs. Variable ROI selection permits profiling of 700-?m diameter areas down to single cells (10-?m). No secondary antibodies or amplification reagents are required. The lab has a sample collection at the IRB approved protocol �Defining human skin immunity to insect vector bites� and FFPE- slides are ready to be tested. On this clinical protocol, we evaluated the human skin response in healthy non-endemic subjects to bites of Anopheles gambiae, Aedes aegypti and Aedes aegypti at different time points after uninfected bites. We will contrast these data with the human skin response in healthy endemic subjects (Cambodians) to bites Aedes aegypti. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.� All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2086069) to Rita Davis at rita.davis@nih.gov, by 2:00 pm eastern standard time August 20, 2021.� All responses received by the closing date of this synopsis will be considered by the Government.� A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/eca3ac0dcf994f7796d9648e7e2c575a/view)
- Place of Performance
- Address: MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN06100532-F 20210819/210817230123 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |